Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease
NCT01006889 on ClinicalTrials.gov · last registry update 2016-09-28
A small phase 4 — 24 participants, against a typical 75. The sponsor logged completion for December 2009. Primary outcome, as filed: Hepatic Steatosis. exenatide is approved in the US, but not for mash nafld — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- COMPLETED
- Phase
- P4
- Drug
- exenatideBydureon, Byetta
- Sponsor
- University of Florida
- Sponsor type
- Other
- Enrollment
- 24
- Started
- 2008-01
- Primary completion
- 2009-12 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Hepatic Steatosis
Conditions studied
Nonalcoholic Fatty Liver Disease · Type 2 Diabetes Mellitus
Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.